Beta Bionics, Inc./$BBNX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Beta Bionics, Inc.
Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company product includes the iLet Bionic Pancreas (iLet). The Company operates as a single segment, focused on the development, manufacture and sale of the iLet.
Ticker
$BBNX
Sector
Primary listing
Employees
407
Headquarters
Website
BBNX Metrics
BasicAdvanced
$1.2B
-
-$2.50
-
-
Price and volume
Market cap
$1.2B
52-week high
$30.47
52-week low
$8.89
Average daily volume
924K
Financial strength
Current ratio
10.636
Quick ratio
9.569
Long term debt to equity
1.936
Total debt to equity
2.608
Profitability
EBITDA (TTM)
-67.327
Gross margin (TTM)
54.51%
Net profit margin (TTM)
-87.89%
Operating margin (TTM)
-77.45%
Revenue per employee (TTM)
$220,000
Management effectiveness
Return on assets (TTM)
-20.08%
Return on equity (TTM)
-47.52%
Valuation
Price to revenue (TTM)
9.415
Price to book
4
Price to tangible book (TTM)
4
Price to free cash flow (TTM)
-13.775
Free cash flow yield (TTM)
-7.26%
Free cash flow per share (TTM)
-1.944
Growth
Revenue change (TTM)
67.01%
Earnings per share change (TTM)
-72.05%
Bulls say / Bears say
Entered a strategic partnership with Abbott to integrate the iLet Bionic Pancreas with Abbott’s future dual glucose-ketone sensor, enhancing device functionality and strengthening competitive differentiation (Nasdaq)
Secured effective formulary agreements with all major pharmacy benefit managers as of July 1, 2025, reducing patient cost barriers and expected to accelerate iLet adoption under pharmacy benefits (Nasdaq)
Achieved a Relative Strength Rating of 83, surpassing the 80-point market-leadership threshold, alongside a reported 54% sales increase, reflecting strong investor interest and growth momentum (Investor’s Business Daily)
Net loss widened to $28.7 million, or 162% of sales, in Q1 2025 compared with $12.4 million a year earlier, underscoring continued unprofitability (Beta Bionics IR)
Gross margin fell to 50.9% in Q1 2025 from 55.7% in Q1 2024, a 482 bp drop that signals rising cost pressures and margin squeeze (Beta Bionics IR)
Despite 54% sales growth, Beta Bionics reported zero percent EPS growth in the latest quarter, highlighting persistent financial leverage and bottom-line challenges (Investor’s Business Daily)
Data summarised monthly by Lightyear AI. Last updated on 7 Oct 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Beta Bionics, Inc. stock?
Beta Bionics, Inc. (BBNX) has a market cap of $1.2B as of October 31, 2025.
What is the P/E ratio for Beta Bionics, Inc. stock?
The price to earnings (P/E) ratio for Beta Bionics, Inc. (BBNX) stock is 0 as of October 31, 2025.
Does Beta Bionics, Inc. stock pay dividends?
No, Beta Bionics, Inc. (BBNX) stock does not pay dividends to its shareholders as of October 31, 2025.
When is the next Beta Bionics, Inc. dividend payment date?
Beta Bionics, Inc. (BBNX) stock does not pay dividends to its shareholders.
What is the beta indicator for Beta Bionics, Inc.?
Beta Bionics, Inc. (BBNX) does not currently have a Beta indicator.